The frontline combination of zanidatamab-hrii (Ziihera) and chemotherapy with or without tislelizumab (Tevimbra) was ...

A few years ago, I had a patient who affectionately went by the name “Pops.” At 85 years young, he was full of life and juggling multiple health issues alongside prostate cancer, yet determined not to ...

When we examine vicarious trauma in Latino and other communities of color, we cannot separate individual experience from the ...

Welcome to Onc Nurse On Call, the new podcast from Oncology Nursing News, hosted by editors-in-chief Patricia Jakel, MN, RN, ...

Look back at the top 5 updates for oncology nurses and advanced practices providers published in 2025. From clinical updates ...

Patient K.C.'s transition from high-risk care to invasive mammary carcinoma treatment under the care and support of a breast cancer advanced practice provider. The patient then obtained testing via ...

Melinda Mayorga, RN, MSN, CNS, AGCNS-BC, OCN, is a clinical nurse specialist at Norris Comprehensive Cancer Center University of Southern California in Los Angeles. Melinda Mayorga, RN, MSN, CNS, ...

The treatment combination of T-DXd and pertuzumab was granted FDA approval in the first-line for unresectable or metastatic HER2-positive breast cancer. The FDA has approved fam-trastuzumab deruxtecan ...